$APTO
Aptose Biosciences Inc.

2019 Q2 Form 10-Q Financial Statement

#000117184319003072 Filed on May 07, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.810M $2.240M $3.700M
YoY Change 12.4% -39.46% 134.18%
% of Gross Profit
Research & Development $3.491M $3.340M $3.140M
YoY Change -55.35% 6.37% 80.98%
% of Gross Profit
Depreciation & Amortization $53.00K $29.00K $16.00K
YoY Change 178.95% 81.25% -30.43%
% of Gross Profit
Operating Expenses $6.346M $5.600M $6.842M
YoY Change -38.56% -18.15% 105.77%
Operating Profit
YoY Change
Interest Expense $130.0K $90.00K $30.00K
YoY Change 85.71% 200.0% 0.0%
% of Operating Profit
Other Income/Expense, Net $128.0K $94.00K $28.00K
YoY Change 91.04% 235.71% -15.15%
Pretax Income -$6.220M -$5.510M -$6.820M
YoY Change -39.38% -19.21% 107.29%
Income Tax
% Of Pretax Income
Net Earnings -$6.218M -$5.506M -$6.814M
YoY Change -39.41% -19.2% 106.99%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$133.8K -$138.3K -$234.8K
COMMON SHARES
Basic Shares Outstanding 43.76M 40.25M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.40M $17.00M $16.20M
YoY Change 91.35% 4.94% 80.0%
Cash & Equivalents $26.90M $16.58M $15.41M
Short-Term Investments $8.500M $400.0K $800.0K
Other Short-Term Assets $168.0K $95.00K $97.00K
YoY Change -18.05% -2.06% -67.67%
Inventory
Prepaid Expenses $722.0K $539.0K $249.0K
Receivables
Other Receivables
Total Short-Term Assets $36.27M $17.66M $16.52M
YoY Change 90.3% 6.9% 77.68%
LONG-TERM ASSETS
Property, Plant & Equipment $352.0K $379.0K $150.0K
YoY Change 52.38% 152.67% -25.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.925M $2.059M $150.0K
YoY Change 733.33% 1272.67% -25.0%
TOTAL ASSETS
Total Short-Term Assets $36.27M $17.66M $16.52M
Total Long-Term Assets $1.925M $2.059M $150.0K
Total Assets $38.19M $19.72M $16.67M
YoY Change 98.0% 18.29% 75.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.240M $1.170M $362.0K
YoY Change 8.2% 223.2% -79.89%
Accrued Expenses $1.486M $1.322M $1.843M
YoY Change 18.41% -28.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $500.0K $500.0K
YoY Change
Total Short-Term Liabilities $3.219M $2.977M $2.205M
YoY Change 34.07% 35.01% 22.5%
LONG-TERM LIABILITIES
Long-Term Debt $1.200M $1.300M $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.200M $1.300M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.219M $2.977M $2.205M
Total Long-Term Liabilities $1.200M $1.300M $0.00
Total Liabilities $4.434M $4.299M $2.200M
YoY Change 84.75% 95.41% 22.22%
SHAREHOLDERS EQUITY
Retained Earnings -$287.4M -$281.1M -$253.6M
YoY Change 8.9% 10.87%
Common Stock $291.2M $267.3M $240.8M
YoY Change 15.08% 10.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $33.76M $15.42M $14.47M
YoY Change
Total Liabilities & Shareholders Equity $38.19M $19.72M $16.67M
YoY Change 98.0% 18.29% 75.52%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$6.218M -$5.506M -$6.814M
YoY Change -39.41% -19.2% 106.99%
Depreciation, Depletion And Amortization $53.00K $29.00K $16.00K
YoY Change 178.95% 81.25% -30.43%
Cash From Operating Activities -$5.269M -$4.874M -$4.054M
YoY Change -42.62% 20.23% 53.27%
INVESTING ACTIVITIES
Capital Expenditures $26.00K $24.00K $24.00K
YoY Change -74.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$8.000M
YoY Change -3300.0%
Cash From Investing Activities -$8.026M -$24.00K -$24.00K
YoY Change -5450.67% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 23.61M 6.178M 8.855M
YoY Change 104.11% -30.23% 140.89%
NET CHANGE
Cash From Operating Activities -5.269M -4.874M -4.054M
Cash From Investing Activities -8.026M -24.00K -24.00K
Cash From Financing Activities 23.61M 6.178M 8.855M
Net Change In Cash 10.32M 1.282M 4.777M
YoY Change 306.82% -73.16% 354.09%
FREE CASH FLOW
Cash From Operating Activities -$5.269M -$4.874M -$4.054M
Capital Expenditures $26.00K $24.00K $24.00K
Free Cash Flow -$5.295M -$4.898M -$4.078M
YoY Change -42.96% 20.11% 54.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 apto Amortization Of Rightof Use Assets
AmortizationOfRightofUseAssets
124000
CY2019Q1 apto Interest On Lease Liabilities
InterestOnLeaseLiabilities
24000
CY2018Q1 apto Interest On Lease Liabilities
InterestOnLeaseLiabilities
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000882361
CY2019Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
Aptose Biosciences Inc.
CY2019Q1 dei Trading Symbol
TradingSymbol
apto
CY2019Q1 apto Operating Lease Right Of Use Asset Gross
OperatingLeaseRightOfUseAssetGross
1804000
CY2019Q1 apto Research And Development Liabilities Current
ResearchAndDevelopmentLiabilitiesCurrent
198000
CY2018Q4 apto Research And Development Liabilities Current
ResearchAndDevelopmentLiabilitiesCurrent
257000
CY2019Q1 apto Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfShares
7300000
CY2019Q1 apto Sharebased Compensation Arrangement By Sharebased Payment Award Maximum Subscription Rate
SharebasedCompensationArrangementBySharebasedPaymentAwardMaximumSubscriptionRate
0.175
CY2019Q1 apto Time Deposits Gross
TimeDepositsGross
440000
CY2018Q4 apto Time Deposits Gross
TimeDepositsGross
458000
CY2019Q1 apto Time Deposits Unrealized Loss
TimeDepositsUnrealizedLoss
-9000
CY2018Q4 apto Time Deposits Unrealized Loss
TimeDepositsUnrealizedLoss
18000
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43764509
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 us-gaap Cash
Cash
1233000
CY2018Q4 us-gaap Cash
Cash
621000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16581000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15299000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2228000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
662000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2228000
CY2019Q1 us-gaap Assets
Assets
19723000
CY2018Q4 us-gaap Assets
Assets
16870000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1170000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1315000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1322000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1474000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4307000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4316000
CY2019Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33625000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32963000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
662000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
17664000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
16486000
CY2019Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
2059000
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
384000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15299000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10631000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16581000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15408000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1282000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4777000
CY2019Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
15348000
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
14678000
CY2019Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2019Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41499112000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38161808000
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41499112000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38161808000
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
267250000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
261072000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5497000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6816000
CY2019Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0.5in"></td> <td style="width: 0.25in"><div style="display: inline; color: #010000">(f)</div></td> <td style="text-align: justify">Concentration of risk:</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company is subject to credit risk from the Company&#x2019;s cash and cash equivalents and investments. The carrying amount of the financial assets represents the maximum credit exposure. The Company manages credit risk associated with its cash and cash equivalents and investments by maintaining minimum standards of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">R1</div>-low or A-low investments and the Company invests only in highly rated Canadian corporations which are capable of prompt liquidation.</div></div></div>
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
2000
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
907000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
955000
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y259D
CY2019Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2190000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2260000
CY2019Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-26000
CY2019Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
2000
CY2018Q1 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-16000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3702000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-145000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-227000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-74000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
667000
CY2019Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-6000
CY2018Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
23000
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-107000
CY2018Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-73000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
92000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
44000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
6842000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
148000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2001000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
119000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
460000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
532000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
521000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
369000
CY2019Q1 us-gaap Liabilities
Liabilities
4299000
CY2018Q4 us-gaap Liabilities
Liabilities
2789000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19723000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16870000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2977000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2789000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6178000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8855000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4874000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4054000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5506000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-6814000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
94000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
28000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
5600000
CY2019Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
124000
CY2018Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1647000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1807000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
485000
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1322000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
99000
CY2018Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1570000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1680000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0542
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y292D
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
217000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
262000
CY2019Q1 us-gaap Other Assets Current
OtherAssetsCurrent
95000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
101000
CY2019Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
9000
CY2018Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
9000
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2019Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
CY2018Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2019Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
539000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
646000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
379000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
384000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3340000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3140000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-281144000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275638000
CY2019Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2018Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
234000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.90
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.939
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0241
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0239
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3237000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.33
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
119000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1414000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.84
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5400000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
662000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2228000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.29
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.14
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4489000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5784000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.11
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.86
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.67
CY2019Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.91
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y73D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y36D
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y
CY2019Q1 us-gaap Short Term Investments
ShortTermInvestments
449000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
440000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
15424000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
14081000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
10202000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
14469000
CY2019Q1 us-gaap Time Deposits At Carrying Value
TimeDepositsAtCarryingValue
449000
CY2018Q4 us-gaap Time Deposits At Carrying Value
TimeDepositsAtCarryingValue
440000
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 0.5in"></td> <td style="width: 0.25in"><div style="display: inline; color: #010000">(c)</div></td> <td style="text-align: justify">Significant accounting policies, estimates and judgments:</td> </tr> </table> <div style=" margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">During the&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>&nbsp;months ended&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019,&nbsp;</div>there have been&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div>&nbsp;changes to our significant accounting policies as described in our Annual Report on Form&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the fiscal year ended&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018,&nbsp;</div>except as described below for Lease accounting.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and reported amounts of assets and liabilities at the date of the consolidated financial statements and reported amounts of revenue and expenses during the reporting period. Actual outcomes could differ from those estimates. The condensed consolidated interim financial statements include estimates, which, by their nature, are uncertain.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The impacts of such estimates are pervasive throughout the condensed consolidated interim financial statements and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require accounting adjustments based on future occurrences.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The estimates and underlying assumptions are reviewed on a regular basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected.</div></div></div>
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39846000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29042000

Files In Submission

Name View Source Status
0001171843-19-003072-index-headers.html Edgar Link pending
0001171843-19-003072-index.html Edgar Link pending
0001171843-19-003072.txt Edgar Link pending
0001171843-19-003072-xbrl.zip Edgar Link pending
apto-20190331.xml Edgar Link completed
apto-20190331.xsd Edgar Link pending
apto-20190331_cal.xml Edgar Link unprocessable
apto-20190331_def.xml Edgar Link unprocessable
apto-20190331_lab.xml Edgar Link unprocessable
apto-20190331_pre.xml Edgar Link unprocessable
exh_101.htm Edgar Link pending
exh_102.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_322.htm Edgar Link pending
f10q_050719p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
logo.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending